Apathy following stroke

Canadian Journal of Psychiatry

Volumn 55, Issue 6, 2010, Pages 350-354

  Jorge, Ricardo E ^a   Starkstein, Sergio E ^b,c   Robinson, Robert G ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FREMANTLE HOSPITAL   (Australia)

Author keywords

Abulia; Apathy; Cerebrovascular disease; Motivation; Stroke

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; NEFIRACETAM; 2 PYRROLIDONE DERIVATIVE; NOOTROPIC AGENT;

APATHY; BASAL GANGLION; BRAIN INFARCTION; CAUDATE NUCLEUS; CEREBROVASCULAR DISEASE; CINGULATE GYRUS; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DATA BASE; DISEASE ACTIVITY; DRUG EFFICACY; FRONTAL CORTEX; GLOBUS PALLIDUS; HUMAN; HYPOTHALAMUS NUCLEUS; MEDLINE; MOTIVATION; NERVE CELL NETWORK; POSTSTROKE DEPRESSION; PREFRONTAL CORTEX; PSYCINFO; REVIEW; STROKE; THALAMUS; THALAMUS INTRALAMINAR NUCLEUS; AFFECTIVE SYMPTOMS; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; DEPRESSIVE DISORDER; DRUG EFFECTS; HEMISPHERIC DOMINANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

AFFECTIVE SYMPTOMS; BRAIN; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEPRESSIVE DISORDER; DOMINANCE, CEREBRAL; HUMANS; MOTIVATION; NERVE NET; NOOTROPIC AGENTS; PYRROLIDINONES; STROKE;

EID: 77953785427     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500603     Document Type: Review

References (50)

1. Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79(10):1088-1092.
2. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916-928. (Pubitemid 43992442)
3. Laplane D, Dubois B. Auto-Activation deficit: a basal ganglia related syndrome. Mov Disord. 2001;16(5):810-814. (Pubitemid 36041181)
4. Habib M. Athymhormia and disorders of motivation in Basal Ganglia disease. J Neuropsychiatry Clin Neurosci. 2004;16(4):509-524. (Pubitemid 39648355)
5. Marin RS, Butters MA, Mulsant BH, et al. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol. 2003;16(2):112-116.
6. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994;182(4):235-239. (Pubitemid 24137682)
7. Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer's disease. Eur J Neurol. 1995;2:540-546.
8. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(Suppl 6):S10-S16.
9. Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15(3):176-183. (Pubitemid 35006772)
10. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17(12):1099-1105. (Pubitemid 35469216)
11. Starkstein SE, Ingram L, Garau LM, et al. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry. 2005;76:1070-1074.
12. Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke. 1993;24(11):1625-1630.
13. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134-139.
14. van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci. 2005;17(1):7-19.
15. Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson's disease. Cambridge (MA): Cambridge University Press; 2002.
16. Starkstein SE, Petracca G, Chemerinski E, et al. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry. 2001;158(6):872-877. (Pubitemid 32547615)
17. Marin RS. Apathy: concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry. 1996;1(4):304-314.
18. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10(3):314-319.
19. Starkstein SE, Garau ML, Cao A. Prevalence and clinical correlates of disinhibition in dementia. Cogn Behav Neurol. 2004;17:139-147. (Pubitemid 39238361)
20. Angelelli P, Paolucci S, Bivona U, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110(1):55-63. (Pubitemid 38822648)
21. Brodaty H, Sachdev PS, Withall A, et al. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke - the Sydney Stroke Study. Psychol Med. 2005;35(12):1707-1716. (Pubitemid 41672349)
22. Hama S, Yamashita H, Shigenobu M, et al. Depression or apathy and functional recovery after stroke. Int J Geriatr Psychiatry. 2007;22(10):1046- 1051. (Pubitemid 47616782)
23. Hama S, Yamashita H, Shigenobu M, et al. Post-stroke affective or apathetic depression and lesion location: left frontal lobe and bilateral basal ganglia. Eur Arch Psychiatry Clin Neurosci. 2007;257(3):149-152. (Pubitemid 46599128)
24. Santa N, Sugimori H, Kusuda K, et al. Apathy and functional recovery following first-ever stroke. Int J Rehabil Res. 2008;31(4):321-326.
25. Starkstein SE, Manes F. Apathy and depression following stroke. CNS Spectr. 2000;5(3):43-50.
26. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(Pt 4):859-876. (Pubitemid 24281846)
27. Bogousslavsky J, Regli F. Anterior cerebral artery territory infarction in the Lausanne Stroke Registry. Clinical and etiologic patterns. Arch Neurol. 1990;47(2):144-150.
28. Kang SY, Kim JS. Anterior cerebral artery infarction: stroke mechanism and clinical-imaging study in 100 patients. Neurology. 2008;70(24 Pt 2):2386-2393.
29. Carrera E, Bogousslavsky J. The thalamus and behavior: effects of anatomically distinct strokes. Neurology. 2006;66(12):1817-1823. (Pubitemid 44049809)
30. Okada K, Kobayashi S, Yamagata S, et al. Poststroke apathy and regional cerebral blood flow. Stroke. 1997;28(12):2437-2441. (Pubitemid 28007646)
31. Glodzik-Sobanska L, Slowik A, Kieltyka A, et al. Reduced prefrontal N-acetylaspartate in stroke patients with apathy. J Neurol Sci. 2005;238(1-2):19-24. (Pubitemid 41560949)
32. Yamagata S, Yamaguchi S, Kobayashi S. Impaired novelty processing in apathy after subcortical stroke. Stroke. 2004;35(8):1935-1940. (Pubitemid 38971879)
33. Schmidt L, d'Arc BF, Lafargue G, et al. Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain. 2008;131(Pt 5):1303-1310.
34. Watanabe A, Matsuo K, Kato N, et al. Cerebrovascular response to cognitive tasks and hyperventilation measured by multi-channel near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci. 2003;15(4):442-449. (Pubitemid 37444587)
35. Van Reekum R, Bayley M, Garner S, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49-53.
36. Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj. 2005;19(2):149-154. (Pubitemid 40259752)
37. Kraus MF. Neuropsychiatric sequelae of stroke and traumatic brain injury: the role of psychostimulants. Int J Psychiatry Med. 1995;25:39-51.
38. Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci. 1995;7(4):502-504.
39. Whyte EM, Lenze EJ, Butters M, et al. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26(3):317-321.
40. Tsuchiya Y, Takahashi Y, Jindo T, et al. Comprehensive evaluation of canine renal papillary necrosis induced by nefiracetam, a neurotransmission enhancer. Eur J Pharmacol. 2003;475(1-3):119-128. (Pubitemid 37088015)
41. Nishizaki T, Matsuoka T, Nomura T, et al. Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol Pharmacol. 1998;53(1):1-5. (Pubitemid 28068366)
42. Kitano Y, Komiyama C, Makino M, et al. Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. Epilepsia. 2005;46(10):1561-1568. (Pubitemid 44921929)
43. Moriguchi S, Marszalec W, Zhao X, et al. Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther. 2003;307(1):160-167. (Pubitemid 37151902)
44. Narahashi T, Moriguchi S, Zhao X, et al. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull. 2004;27(11):1701-176. (Pubitemid 41701591)
45. Zhao X, Yeh JZ, Narahashi T. Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann NY Acad Sci. 2001;939:179-186.
46. Ando T, Takagi N, Takagi K, et al. Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats. Eur J Pharmacol. 2005;507(1-3):49-56. (Pubitemid 40126840)
47. Jin J, Watabe S, Yamamoto T. Nefiracetam improves the impairment of local cerebral blood flow and glucose utilization after chronic focal cerebral ischemia in rats. Pharmacology. 2002;64(3):119-125. (Pubitemid 34136852)
48. Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008;20(2):178-184.
49. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
50. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243-254.